-
Product Insights
Coagulation Factor X – Drugs In Development, 2023
Global Markets Direct’s Coagulation Factor X provides in depth analysis on Coagulation Factor X targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor X targeted therapeutics...
-
Product Insights
Recessive X Chromosome Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Recessive X Chromosome Disorders - Drugs In Development, 2023’, provides an overview of the Recessive X Chromosome Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Coagulation Factor II (human) + Coagulation Factor VII (human) + Coagulation Factor IX (human) + Coagulation Factor X (human) + Protein C (human)) in Blood Coagulation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Coagulation Factor II (human) + Coagulation Factor VII (human) + Coagulation Factor IX (human) + Coagulation Factor X (human) + Protein C (human)) in Blood Coagulation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine...
-
Product Insights
X Linked Retinitis Pigmentosa GTPase Regulator – Drugs In Development, 2023
Global Markets Direct’s X Linked Retinitis Pigmentosa GTPase Regulator provides in depth analysis on X Linked Retinitis Pigmentosa GTPase Regulator targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
C-X-C Chemokine Receptor Type 4 – Drugs In Development, 2023
Global Markets Direct’s C-X-C Chemokine Receptor Type 4 provides in depth analysis on C-X-C Chemokine Receptor Type 4 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C...
-
Product Insights
C-X-C Chemokine Receptor Type 2 – Drugs In Development, 2023
Global Markets Direct’s C-X-C Chemokine Receptor Type 2 provides in depth analysis on C-X-C Chemokine Receptor Type 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C...
-
Product Insights
C-X-C Chemokine Receptor Type 3 – Drugs In Development, 2023
Global Markets Direct’s C-X-C Chemokine Receptor Type 3 provides in depth analysis on C-X-C Chemokine Receptor Type 3 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C...
-
Product Insights
C-X-C Chemokine Receptor Type 1 – Drugs In Development, 2023
Global Markets Direct’s C-X-C Chemokine Receptor Type 1 provides in depth analysis on C-X-C Chemokine Receptor Type 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C...
-
Product Insights
C-X-3-C Motif Chemokine Receptor – Drugs In Development, 2023
Global Markets Direct’s C-X-3-C Motif Chemokine Receptor provides in depth analysis on C-X-3-C Motif Chemokine Receptor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-3-C Motif Chemokine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexanolone in Fragile X Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Fragile X Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Fragile X Syndrome Drug Details: Brexanolone is under...